{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:26:16Z","timestamp":1793316376693,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.leukres.2013.01.004","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T23:30:54Z","timestamp":1360711854000},"page":"609-613","source":"Crossref","is-referenced-by-count":114,"title":["Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine"],"prefix":"10.1016","volume":"37","author":[{"given":"Lionel","family":"Ad\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wolfromm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Teichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon V.","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.01.004_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.004_bib0010","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French\u2013American\u2013British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.01.004_bib0015","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML \u2013 dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.01.004_bib0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.004_bib0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2013.01.004_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.004_bib0035","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.004_bib0040","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.004_bib0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.004_bib0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.01.004_bib0055","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.004_bib0060","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.004_bib0065","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.004_bib0070","series-title":"ASH Annual Meeting Abstracts","first-page":"125","article-title":"Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients","author":"Kulasekararaj","year":"2010"},{"key":"10.1016\/j.leukres.2013.01.004_bib0075","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.004_bib0080","article-title":"High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study","author":"Fianchi","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.01.004_bib0085","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review","volume":"36","author":"Thorpe","year":"2012","journal-title":"Leuk Res"},{"issue":"October","key":"10.1016\/j.leukres.2013.01.004_bib0090","first-page":"3","article-title":"Treatment of chronic myelomonocytic leukemia with azacitidine","author":"Wong","year":"2012","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T07:00:29Z","timestamp":1595401229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0145212613000180"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.01.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}